A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL)
Latest Information Update: 19 Feb 2025
At a glance
- Drugs Lisocabtagene-maraleucel (Primary)
- Indications B-cell lymphoma; CNS cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms TRANSCEND; TRANSCEND NHL 001
- Sponsors Juno Therapeutics
Most Recent Events
- 09 Dec 2024 According to a Bristol Myers Squibb media release, data from this study were presented at the 66 th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, California.
- 19 Nov 2024 According to a Bristol Myers Squibb media release, results from this trial will be presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, to be held from December 7 to 10 in San Diego, California.
- 27 Jun 2024 Status changed from active, no longer recruiting to completed.